ERGO Share PerformanceMore
|52 week high||172.00 08/01/16|
|52 week low||117.00 16/09/16|
|52 week change||-30.00 (-19.11%)|
|4 week volume||560,743 02/10/16|
Latest News« previous» nextMore
24/10/2016 - 07:57 StockMarketWire
Ergomed says it is pleased to note that its co-development partner Dilaforette has today announced its intention to undertak...
24/10/2016 - 07:00 RNS
RNS Number: 2180N Ergomed plc 24 October 2016 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed notes co-development partner Dilaforette's intention to conduct an Initial Public Offering and change of name to Modus Therapeutics London, UK - 24 October 2016: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a clinical trial services and drug ...
21/10/2016 - 12:40 StockMarketWire
N+1 Singer today reaffirms its buy investment rating on Ergomed Plc (LON:ERGO) and raised its price target to 265p (fro...
14/10/2016 - 07:00 RNS
RNS Number: 5082M Ergomed plc 14 October 2016 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed's co-development partner Aeterna Zentaris, Inc. announces a fourth licensing agreement for Zoptrex, this time with Specialised Therapeutics Asia for Australia and New Zealand London, UK - 14 October 2016: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the C...
26/09/2016 - 07:07 StockMarketWire
26/09/2016 - 07:00 RNS
RNS Number: 7528K Ergomed plc 26 September 2016 PRESS RELEASE Unaudited Interim results for the six months ended 30 June 2016 Strong first half financial performance - revenues up 21% and gross profit up 26% 19 million new contracts signed resulting in a backlog of 60 million Acquisitions of O+P and GASD strengthens service business Acquisition of Ha...
22/09/2016 - 09:22 StockMarketWire
Ergomed says that following its recent acquisitions of Dr Oestreich + Partner and Gesellschaft fr angewandte Statistik + D...
22/09/2016 - 07:00 RNS
RNS Number: 4981K Ergomed plc 22 September 2016 Ergomed's full service contract win validates strategic rationale of recent acquisitions London, UK - 22 September 2016: Ergomed plc, (LSE: ERGO or 'Ergomed' or "the Group") announces that, following its recent acquisitions of Dr. Oestreich + Partner GmbH ('O+P') and Gesellschaft fr angewandte Statistik + Date...
|Dividend yield||0 %|
Equity Research (ERGO)
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. It has unusually high revenue visibility, indeed...
Latest discussion posts More
“We will be hosting a webinar with the management of Ergomed tomorrow (Tuesday 27th September) at 11.15. There will be a presentation of the interim results lasting around ...”▼
Codes & Symbols
|Symbols||ERGO, LSE:ERGO, ERGO.L, ERGO:LN, LON:ERGO, XLON:ERGO|